REOLYSIN + Carboplatin + Paclitaxel + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Squamous Cell of the Head and Neck
Conditions
Carcinoma, Squamous Cell of the Head and Neck
Trial Timeline
Jun 1, 2010 → May 1, 2014
NCT ID
NCT01166542About REOLYSIN + Carboplatin + Paclitaxel + Placebo
REOLYSIN + Carboplatin + Paclitaxel + Placebo is a phase 3 stage product being developed by Oncolytics Biotech for Carcinoma, Squamous Cell of the Head and Neck. The current trial status is completed. This product is registered under clinical trial identifier NCT01166542. Target conditions include Carcinoma, Squamous Cell of the Head and Neck.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Squamous Cell of the Head and Neck were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01166542 | Phase 3 | Completed |
Competing Products
20 competing products in Carcinoma, Squamous Cell of the Head and Neck